Stoke Therapeutics, Inc. STOK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $155.66M-43.4% | $84.22M-34.2% | $83.39M-44.4% | $101.47M-47.6% | $274.82M+53.9% | ||
| $187.89M+128% | $200.45M— | $164.92M— | $146.24M— | $82.51M— | ||
| —— | —— | —— | —— | $3.02M— | ||
| $366.68M-2.4% | $305.7M+31.3% | $272.44M+7.4% | $269.97M-9.1% | $375.74M+94.4% | ||
| $3.4M-6.0% | $3.15M-19.5% | $3.08M-28.8% | $3.34M-29.9% | $3.61M-31.6% | ||
| $443.28M+8.9% | $418.43M+54.1% | $360.26M+22.8% | $384.51M+24.9% | $406.89M+98.3% | ||
| $6.84M+213% | $4.94M+97.7% | $5.87M+136% | $4.31M+9.3% | $2.19M+4.0% | ||
| $6.6M— | $6.96M— | —— | —— | —— | ||
| $40.81M-8.7% | $57.88M+44.5% | $41.73M-16.3% | $38.68M-13.1% | $44.69M+25.6% | ||
| $7.59M-37.4% | $8.1M+227% | $10.43M-8.0% | $10.89M-47.0% | $12.13M-58.5% | ||
| $48.4M-14.8% | $65.98M+55.1% | $52.16M-14.8% | $49.57M-23.8% | $56.81M-12.4% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| -$547.72M-44.9% | -$497.72M-1.4% | -$439.78M+8.4% | -$401.43M+11.6% | -$377.95M+11.7% | ||
| $394.88M+12.8% | $352.46M+53.9% | $308.11M+32.7% | $334.94M+38.0% | $350.07M+149% | ||
| $443.28M+8.9% | $418.43M+54.1% | $360.26M+22.8% | $384.51M+24.9% | $406.89M+98.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Stoke Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.99 — current assets exceed current liabilities.
- Where does Stoke Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.